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Background: In order to characterize the functional properties of canine protein C (CnPC), the zymogen needs to
be purified from plasma. The goals of this study were (1) to purify protein C from fresh frozen canine plasma by
barium chloride and ammonium sulphate precipitation, followed by immunoaffinity chromatography using a
monoclonal mouse antibody against human protein C (HPC4) and (2) to characterize this protein’s structure.
Results: The purified protein contained three glycosylated forms of a heavy chain (~49 kDa) and a glycosylated
light chain (~25 kDa). Tandem mass spectra of the peptides obtained following trypsin digestion and liquid
chromatography identified this protein to be protein C (vitamin K-dependent protein C precursor, gi|62078422) with
100% probability. Three glycosylation sites (Asn139, Asn202, and Asn350) were identified by detection of peptides
containing an N-linked glycosylation consensus sequon with a 3-dalton increase in mass following incubation of
the protein with PNGase F in 18O-labeled water. Following incubation with Protac (a specific activator of protein C),
the heavy chain showed a slight decrease in molecular size and amidolytic activity measured by a synthetic
chromogenic substrate containing an amide bond [H-D-(γ-carbobenzoxyl)-lysyl-prolyl-arginine-paranitroanilide
diacetate salt]. The amidolytic activity was increased by ~303-fold in the final protein preparation compared to that
in plasma. The purified protein showed concentration-dependent anti-factor V and anti-factor VIII activities in canine
plasma in coagulometric factor assays.
Conclusions: These studies showed that CnPC could be purified from plasma using HPC4 and that this protein
showed amidolytic and anti-coagulant properties upon activation with Protac.
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Activated protein C (APC) is a natural anticoagulant in
plasma. It is derived from protein C zymogen, which is
synthesized by hepatocytes and circulates in plasma at low
concentration. Upon activation by thrombin, APC inhibits
factor V (FV) and factor VIII (FVIII) activities by irrevers-
ible proteolysis [1,2]. Recombinant human activated
protein C (rhAPC) was previously available as drotrecogin
alpha (activated) (Xigris, Eli Lilly & Company, Indianapolis,
IN) and approved for treatment of sepsis in patients with
high risk of death by the United States Food and Drug
Administration (FDA) and European Medicines Agency
(EMEA) based on results obtained from the Recombinant
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unless otherwise stated.Severe Sepsis (PROWESS) study [3]. A subsequent trial,
PROWESS-SHOCK, showed no difference in the 28-day or
90-day mortality rates between the Xigris and placebo
groups [4]. Furthermore, a systematic review of six ran-
domized clinical trials, including the two aforementioned
studies, showed no efficacy of treatment with Xigris in
sepsis [5]. The manufacturer of Xigris eventually announced
the withdrawal of Xigris from the market worldwide on
October 25, 2011 [6].
Despite the lack of clinical efficacy of Xigris for treating
sepsis, the anti-inflammatory and cytoprotective effects of
protein C are well established. It has also been shown that
the anticoagulant effects of APC are not required for
protecting septic mice against mortality [7]. An advantage
of using non-coagulant APC variants, as opposed to the
anticoagulant wild-type APC, in a clinical setting is
reduced risk of bleeding, as the use of Xigris in human
sepsis was associated with increased risk of serious bleeding
[8]. Furthermore, some APC variants conferred a higher
degree of cytoprotection than wild-type APC [9,10].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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protein C (CnPC) zymogen is very similar to that for
humans, consisting of nine exons and conserved exon/
intron boundaries [11]. Computational analysis of CnPC
cDNA predicted that CnPC had 456 amino acids and was
72.1% similar to human protein C [11]. Furthermore, in
naturally occurring sepsis for both species, reduced circu-
lating protein C activities were noted and early increase in
protein C levels during hospitalization were of positive
prognostic value [12-16]. The biological properties of
CnPC are not as well established as those for human
protein C. Given the therapeutic potential of rhAPC and
human APC variants, the therapeutic potential of CnPC
or canine activated protein C (CnAPC) warrants investiga-
tion. To facilitate such investigation, CnPC needs to be
purified so that its precise structure and function may be
determined. Knowledge of the CnPC pathway could
potentially benefit canine patients and enhance our under-
standing of the protein C pathway in other species.
In this manuscript, we describe a method for purifying
CnPC zymogen from fresh frozen plasma by salt precipita-
tion followed by immunoaffinity chromatography using an
antibody directed against a peptide sequence on human
protein C (clone HPC4). This method was modified from a
method described by Stenflo et al. for isolating protein C
from fresh bovine plasma [17].
Results
A plasma protein was markedly enriched over the course of
the purification process, which consisted of two major
parts: salt precipitation (barium sulphate precipitation
followed by ammonium sulphate precipitation) and immu-
noaffinity chromatography using a monoclonal antibody
that targets the amino acid sequence EDQVDPRLIDGK of
human protein C. On a silver-stained non-reducing sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) of the different plasma protein fractions obtained at
various stages of the purification process, this protein was
not readily discernable until after immunoaffinity chroma-
tography (Figure 1A). However, Western immunoblotting
with a polyclonal antibody detected this protein in small
quantities in the plasma protein fraction obtained after salt
precipitation and in much greater (37.6-fold increase)
amounts in the eluate obtained from immunoaffinity chro-
matography (Figure 1B-D). This protein showed strong
immunoreactivity for a polyclonal antibody against human
protein C, while no other plasma proteins in human
protein C-deficient plasma or canine plasma showed such
immunoreactivity (Figure 2). Furthermore, using domain-
enhanced lookup time-accelerated BLAST (DELTA-BLAST)
[18] to search the Swissprot database for canis lupus
familiaris, only CnPC (accession number Q28278.2) was
found to show significant alignment with the sequence
EDQVDPRLIDGK.The peptide mass spectra obtained following in-gel tryp-
sin digestion and liquid chromatography followed by tan-
dem mass spectral analysis (LC-MS/MS) identified
protein C (vitamin K-dependent protein C precursor, gi|
62078422) in all silver-stained protein bands with 100%
probability. Table 1 shows a summary of the spectra
assigned to identification of protein C in each protein
band. Table 2 shows a summary of the mass spectral
data for each excised band. Only protein C was identi-
fied in the three closely spaced bands seen at ~49 kDa
(MW of the three bands were estimated to be:
49 kDa, 44 kDa, and 40 kDa) and a band at ~25 kDa
(Figure 3). Protein C was also identified in other
bands (~129 kDa, ~107 kDa, and ~75 kDa) (Figure 3).
The 75-kDa band may represent the single chain form of
protein C, which is also found in human plasma. However,
Western immunoblotting using antibodies against human
protein C did not detect immunoreactivity in the 75-kDa
region in reduced CnPC (Figure 2B). No further studies
were performed to assess whether or not single-chain
form of protein C was in canine plasma. Apolipoprotein
A-1 was present in a band at ~25 kDa. Complement C3
was present in two bands at ~129 kDa and ~75 kDa.
The structure of the purified protein showed many simi-
larities with human protein C. The protein migrated as two
tightly spaced bands of ~75 kDa under non-reducing con-
ditions (Figures 1 and 4); and as three tightly spaced bands
of ~49 kDa and a much smaller band of ~25 kDa (Figure 2).
The results suggest that the protein consisted of two chains
linked by at least one disulphide bond. To show the tightly
spaced bands were different glycosylated forms, as opposed
to different peptides or different degraded forms of the
same peptide, the protein was reduced and then deglycosyl-
ated in a mixture of deglycosylation enzymes. The protein
was first reduced to allow better access of the enzymes to
their substrates. Following glycosylation, the three tightly
spaced bands seen at ~49 kDa were no longer detected on
SDS-PAGE (12%, silver-stained) (Figure 3). A smaller, single
band was seen at ~27 kDa instead, suggesting that the three
tightly spaced bands were indeed different glycosyated
forms of the same peptide. The 25-kDa band that was seen
with the parent form of the protein was also no longer de-
tectable after deglycosylation. Instead, a new, smaller band
was seen at ~23 kDa, suggesting that the parent form of
this peptide was glycosylated as well (Figure 3). To deter-
mine the exact N-linked glycosylated sites of this protein,
we searched the amino acid sequence of the protein for the
consensus sequences (also known as sequons) N-X-T and
N-X-S. The following four sites were identified: Asn139,
Asn202, Asn289, and Asn350. It is recognized that these
sequons are not the only requisite for N-linked glycosyla-
tion to occur [19,20]. To confirm N-linked glycosylation at
these four sites, isotope-coded glycosylation site-specific
tagging (IGOT) [21] was performed. This method is based
Figure 1 Purification of CnPC from plasma by immunoaffinity chromatography using HPC4. (A) Silver stained non-reduced 12% SDS-PAGE
showing plasma protein fractions obtained over the course of purification. Five μg of protein was loaded into each lane. Lane 1: Whole plasma.
Lane 2: Plasma protein fraction obtained after salt precipitation and exclusion of protein <30 kDa in size. Lane 3: Plasma protein fraction in the salt
precipitate that did not bind to react with HPC4. Lane 4: Proteins obtained after salt precipitation and immunoaffinity purification. Proteins
were ~75 kDa in size and migrated as two tightly spaced bands. Lane 5: Molecular weight markers. (B) Western blot of gel in (A) with antibody
to peptide EDQVDPRLIDGK. Lane loads were the same as (A). A faint band was present after salt precipitation and removal of small proteins
(lane 2). This band was more prominent after immunoaffinity purification (lane 4). (C) Densitometry profile of lane 2 in (B). (D) Densitometry
profile of lane 4 in (B). This band was 37.59 times as dense as the highlighted band in lane 2.
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Figure 2 A polyclonal anti-protein C antibody specifically detecting CnPC in plasma. (A) Silver stained reducing 12% SDS-PAGE of human
protein C-deficient plasma and with added CnPC. Lane 1: CnPC (0.5 μg) purified from canine plasma. Lane 2: Human protein C-deficient plasma
(5 μg of protein). Lane 3: Human protein C-deficient plasma (5 μg of protein) spiked with 0.5 μg of CnPC. Lane 4: Molecular weight markers.
(B) Western blot of gel in (A) probed with a polyclonal antibody to EDQVDPRLIDGK. Lane loads were the same as (A). Two tightly spaced bands
(likely two glycoforms) were present in lanes 1 and 3, indicating detection of CnPC. Only the major glycoform was visible in lane 1 in (A), and this
was likely related to lower sensitivity of silver staining than western immunoblotting.
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from the Asn residue, it deamidates Asn, converting it into
an Asp residue. During this process, an oxygen ion from a
water molecule is incorporated into the new Asp residue,
which makes it 1 dalton heavier than the predicted Asn
residue. Given that natural deamidation of Asn residues is
known to occur, a more definitive way to show that deami-
dation is due to the action of PNGase F is to incorporate a
labeled oxygen ion, such as 18O-labelled water. Deamida-
tion of Asn 18O-labelled water will result in incoporation of
an oxygen ion that is 2 daltons heavier than the H2
16O,
which is the more abundant form found in nature. This
reaction will result in a 3-dalton mass shift, which is very
unlikely to be a natural occurrence. By use of IGOT, three
of the potential N-linked glycosylated sites were found to
show a 3-dalton increase in mass: Asn139, Asn202, and
Asn289 (Figures 5 and 6). The fourth N-linked glycosylated
site (Asn350) was not captured on mass spectrometry on
multiple attempts. Therefore, the glycosylation status of this
site remains unknown.
Both human [22,23] and CnPC [12,13,24] are known to
show amidolytic activity following incubation with Protac.
For human protein C, Protac removes a peptide from the
heavy chain, thereby exposing the catalytic site, which
cleaves FV and FVIII, as well as the synthetic chromogenic
substrate Spectrozyme. To show that the protein purified
in this study shared these properties, we investigated its
amidolytic activity in a plasma-free system and effects on
FV and FVIII activities in canine plasma. Following incuba-
tion with Protac, the protein showed amidolytic activities
that were directly proportional to the protein concentration
(Figure 7A and B). Such activities appeared to be enriched
during the purification process as well. Initial attempts to
detect protein C amidolytic activities in plasma and the saltprecipitate using final protein concentrations of 10 μg/mL
did not yield consistently detectable amidolytic activities.
Activity was only detected when the final protein concen-
tration was increased to 100 μg/mL (Figure 7C). Com-
pared to plasma, the amidolytic activities of CnPC was
increased by ~8.19-fold after salt precipitation and (after
adjustment for the final protein concentration used in the
assay) ~303-fold following immunoaffinity chromtagraphy
(i.e. CnPC activity was enriched ~37.6 times in the final
purified form compared to that in the salt precipitate).
These results corroborated with results obtained by western
immunoblotting using anti-protein C tag antibody.
The preservation of amidolytic activities of the purified
protein suggested to us that the protein would most likely
retain its anticoagulant properties as well. To confirm this,
the effects of this protein (following activation in vitro by
Protac) on the activities of FV and FVIII in canine plasma
were determined. As predicted, activated form of the pro-
tein inhibited the activities of these coagulation factors in
a concentration-dependent manner (Figure 8).
Other researchers have concluded that human and
CnPC share structural similarities when comparing the ex-
pression sequences between the two species [11]. More
specifically, they predicted that CnPC was synthesized as a
single-chain protein, which was processed into a double-
chain protein by removal of a dipeptide adjoining the two
chains, accompanied by removal of a signal peptide at the
N-terminus. We performed N-terminal sequencing of the
light and heavy chains of the purified protein, as well as
the Protac-activated heavy chain to determine if findings at
the protein level would corroborate with predictions based
on alignment of the canine and human expression se-
quences. Edman sequencing showed that the N-terminus
of the light chain began as: ANSFL, and that of the heavy
Table 1 Peptide sequences from LC-MS/MS confirming identify of protein C
Band Sequence Probability Ion score Identity score
HCα (R)DAcEGDSGGPMVTSFR(G) 95% 62.74 25.00
(R)DAcEGDSGGPmVTSFR(G) 95% 77.48 25.00
(R)eLTQVGQETVVTGWGYR(S) 95% 50.45 31.31
(R)ELTQVGQETVVTGWGYR(S) 95% 39.26 31.38
(R)ELTQVGQETVVTGWGYR(S) 95% 47.03 31.38
(R)ELTQVGQETVVTGWGYR(S) 95% 70.81 31.38
(K)GEmDVDIK(E) 95% 49.08 27.51
(R)GESPWQVVLLDSK(K) 95% 71.42 30.85
(R)GESPWQVVLLDSKK(K) 95% 30.54 30.09
(R)GESPWQVVLLDSKK(K) 95% 63.18 30.09
(R)GTWFLVGLVSWGEGcGR(L) 95% 67.5 31.20
(R)GTWFLVGLVSWGEGcGR(L) 95% 59.65 31.20
(R)HcScAPGYR(L) 95% 30.75 25.00
(R)LGEYDLR(R) 95% 37.33 28.93
(R)LGEYDLR(R) 95% 37.66 28.70
(R)LGEYDLR(R) 95% 38.07 28.93
(R)LGEYDLR(R) 95% 41.16 28.70
(R)LVNGKVTR(R) 95% 51.78 27.82
(R)RGESPWQVVLLDSK(K) 95% 40.51 30.07
(R)RGESPWQVVLLDSK(K) 95% 41.43 30.25
(R)RGESPWQVVLLDSK(K) 95% 41.91 30.07
(R)RGESPWQVVLLDSK(K) 95% 52.68 30.25
(R)RGESPWQVVLLDSK(K) 95% 45.81 30.22
(R)RGESPWQVVLLDSKK(K) 95% 54.73 28.60
(R)RGESPWQVVLLDSKK(K) 95% 55.67 28.61
(K)STTDNDIALLHLAQPAIFSQTIVPIcLPDSGLAER(E) 95% 58.73 26.59
(R)YLDWIHSHIR(G) 95% 38.67 30.04
(R)YLDWIHSHIR(G) 95% 42.28 30.12
(R)YLDWIHSHIR(G) 95% 43.78 30.12
(R)YLDWIHSHIR(G) 95% 33.04 30.12
HCβ (R)DAcEGDSGGPmVTSFR(G) 95% 82.07 25.00
(R)DTNQTDQIDPR(L) 95% 43.85 27.71
(R)DTNQTDQIDPR(L) 95% 44.08 27.76
(R)DTNQTDQIDPR(L) 95% 43.09 26.50
(R)ELTQVGQETVVTGWGYR(S) 95% 37.28 31.21
(R)eLTQVGQETVVTGWGYR(S) 95% 40.06 31.36
(R)eLTQVGQETVVTGWGYR(S) 95% 57.46 31.32
(R)ELTQVGQETVVTGWGYR(S) 95% 45.45 31.38
(R)ELTQVGQETVVTGWGYR(S) 95% 72.84 31.35
(R)ELTQVGQETVVTGWGYR(S) 95% 50.99 31.29
(R)ELTQVGQETVVTGWGYR(S) 95% 82.28 31.46
(R)eLTQVGQETVVTGWGYR(S) 95% 82.84 31.33
(K)EVLIHPNYSK(S) 95% 38.95 29.96
(K)EVLIHPNYSK(S) 95% 53.99 29.85
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Table 1 Peptide sequences from LC-MS/MS confirming identify of protein C (Continued)
(K)GEmDVDIK(E) 95% 48.54 27.81
(R)GESPWQVVLLDSK(K) 95% 83.15 30.54
(R)GTWFLVGLVSWGEGcGR(L) 95% 62.12 31.30
(R)GTWFLVGLVSWGEGcGR(L) 95% 52.34 31.20
(R)LGDDHLQcQPAVK(F) 95% 29.27 30.38
(R)LGEYDLR(R) 95% 36.72 28.93
(R)LGEYDLR(R) 95% 38.59 28.93
(R)RGESPWQVVLLDSK(K) 95% 43.76 30.07
(R)RGESPWQVVLLDSK(K) 95% 48.35 30.24
(R)RGESPWQVVLLDSK(K) 95% 52.51 30.22
(R)RGESPWQVVLLDSK(K) 95% 45.78 30.20
(R)RGESPWQVVLLDSKK(K) 95% 56.17 28.62
(R)YLDWIHSHIR(G) 95% 27.58 30.04
(R)YLDWIHSHIR(G) 95% 45.55 29.51
HCγ (R)DAcEGDSGGPmVTSFR(G) 95% 55.88 25.00
(R)eLTQVGQETVVTGWGYR(S) 95% 74.58 31.37
(R)ELTQVGQETVVTGWGYR(S) 95% 84.14 31.35
(R)GEEASLENQVP(-) 95% 36.07 27.59
(R)GESPWQVVLLDSK(K) 95% 54.73 30.81
(R)GTWFLVGLVSWGEGcGR(L) 95% 44.16 31.21
(R)GTWFLVGLVSWGEGcGR(L) 95% 71.82 31.35
(R)LGEYDLR(R) 95% 39.46 28.78
(R)RGESPWQVVLLDSK(K) 95% 48.08 30.23
(R)RGESPWQVVLLDSK(K) 95% 44.88 30.07
(R)YLDWIHSHIR(G) 95% 39.9 30.10
LC (R)DTnQTDQIDPR(L) 95% 48.54 26.91
(R)ELTQVGQETVVTGWGYR(S) 95% 36.27 31.38
(R)ELTQVGQETVVTGWGYR(S) 95% 89.79 31.45
(R)GTWFLVGLVSWGEGcGR(L) 95% 75.93 31.30
(R)HcScAPGYR(L) 95% 33.4 25.00
(R)HcScAPGYR(L) 95% 42.26 25.00
(R)HcScAPGYR(L) 95% 45.5 25.00
(R)LGEYDLR(R) 95% 39.5 28.78
(R)RGESPWQVVLLDSK(K) 95% 47.81 30.23
(R)RGESPWQVVLLDSK(K) 95% 53.34 30.22
HCd (R)DAcEGDSGGPmVTSFR(G) 95% 81.66 25.00
(R)DTnQTDQIDPR(L) 95% 42.7 26.58
(R)ELTQVGQETVVTGWGYR(S) 95% 41.89 31.35
(R)ELTQVGQETVVTGWGYR(S) 95% 85.33 31.30
(R)eLTQVGQETVVTGWGYR(S) 95% 93.64 31.37
(K)EVLIHPnYSK(S) 95% 39.21 30.08
(K)EVLIHPnYSK(S) 95% 47.75 29.87
(K)eVLIHPnYSK(S) 95% 57.75 28.94
(K)EVLIHPnYSK(S) 95% 60.43 30.12
(R)GESPWQVVLLDSK(K) 95% 67.05 30.81
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Table 1 Peptide sequences from LC-MS/MS confirming identify of protein C (Continued)
(R)GTWFLVGLVSWGEGcGR(L) 95% 69.72 31.25
(R)HcScAPGYR(L) 95% 29.11 25.00
(R)RGESPWQVVLLDSK(K) 95% 39.91 30.23
(R)RGESPWQVVLLDSK(K) 95% 39.82 30.23
(R)RGESPWQVVLLDSKK(K) 95% 54.93 28.60
(R)YLDWIHSHIR(G) 95% 30.81 30.12
(R)YLDWIHSHIR(G) 95% 43.69 30.11
LCd (R)ELTQVGQETVVTGWGYR(S) 95% 32.58 31.36
(R)ELTQVGQETVVTGWGYR(S) 95% 85.2 31.30
(R)HcScAPGYR(L) 95% 31.91 25.00
(R)HcScAPGYR(L) 95% 32.88 25.00
(R)LGEYDLR(R) 95% 41.34 28.93
X (R)DTNQTDQIDPR(L) 95% 33.05 27.71
(R)ELTQVGQETVVTGWGYR(S) 95% 25.29 31.31
(R)ELTQVGQETVVTGWGYR(S) 95% 90.91 31.38
(R)GEEASLENQVP(-) 95% 34.55 27.73
(R)GESPWQVVLLDSK(K) 95% 67.83 30.85
(R)LGDDHLQcQPAVK(F) 95% 23.14 30.39
(R)LGEYDLR(R) 95% 37.69 28.78
(R)RGESPWQVVLLDSK(K) 95% 42.97 30.05
(R)RGESPWQVVLLDSK(K) 95% 40.33 30.07
(R)YLDWIHSHIR(G) 95% 39.48 29.71
Y (R)ELTQVGQETVVTGWGYR(S) 95% 31.23 31.29
(R)ELTQVGQETVVTGWGYR(S) 95% 67.41 31.30
(R)HcScAPGYR(L) 95% 28.9 25.00
(R)LGDDHLQcQPAVK(F) 95% 24.31 30.32
(R)LGEYDLR(R) 95% 41.34 28.93
(R)RGESPWQVVLLDSK(K) 95% 25.09 30.05
Z (R)ELTQVGQETVVTGWGYR(S) 95% 31.01 31.35
(R)ELTQVGQETVVTGWGYR(S) 95% 97.66 31.32
(K)GEmDVDIK(E) 95% 38.24 27.82
(R)GESPWQVVLLDSK(K) 95% 75.58 30.85
(R)LGDDHLQcQPAVK(F) 95% 40.02 30.39
(R)LGEYDLR(R) 95% 41.54 28.93
(R)RGESPWQVVLLDSK(K) 95% 28.86 30.07
(R)RGESPWQVVLLDSK(K) 95% 41.52 30.24
(R)YLDWIHSHIR(G) 95% 25.66 30.11
Bands as shown in Figure 3. Letters in lower case indicate either oxidation of methionine (m), carbamidomethyl cysteine (c), deamidation of asparagine (n) or
pyroglutamate (e).
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amino acid (a glycosylated asparagine in this case). These
results corroborated with the predictions. Following incu-
bation with Protac, CnPC showed a decrease in molecular
weight (Figure 9), and the N-terminus of the heavy chain
was determined to be GVNGK by Edman sequencing.
However, CnPC cDNA obtained by us (data not shown)and others [11,25] showed that the amino acid residue
prior to VNGK should be a leucine, and LC-MS/MS re-
sults showed that this amino acid at this position in the
peptide had a mass consistent with either leucine or isoleu-
cine (the only two natural amino acids that share the exact
same mass). We concluded that the N-terminal sequence
of Protac-digested heavy chain was likely LVNGK, and the
Table 2 Summary of LC-MS/MS results
Band Vitamin K-dependent protein C precursora Apolipoprotein A-1 (predicted)b Complement C3 (predicted)c Albumind
HCα 30 (13,19), 30%
HCβ 28 (12,16), 27%
HCϒ 11 (8,10), 20%
LC 10 (6,8), 16%
HCd 17 (10,13), 23%
LCd 7 (7,7), 30%
Band X 10 (8,10), 18% 10 (23,24), 15% 24 (3,3), 6%
Band Y 6 (5,6), 13%
Band Z 9 (7,9), 15% 12 (11,12), 9% 22 (18,21), 33%
Bands according to Figure 3. Entries denote number of assigned spectra (number of unique peptides, number of unique spectra), percent coverage. Only proteins





Wong et al. BMC Veterinary Research 2014, 10:251 Page 8 of 18
http://www.biomedcentral.com/1746-6148/10/251glycine detected was probably from a second protein or
peptide present in the sample.
Discussion
In this study, we showed that a method involving salt pre-
cipitation followed by immunoaffinity chromatographyFigure 3 Silver-stained reducing SDS-PAGE of CnPC before and
after deglycosylation. Lane 1: Molecular weight markers. Lane 2: Protein
C purified from canine plasma consists of a heavy chain (HC) with three
glycosylated forms (α, β, and γ) and a glycosylated light chain (LC). Lane
3: The same preparation shown in lane 2 treated with deglycosylation
enzyme mixture. The heavy chain had decreased MW and migrated as a
single band (HCd), suggesting CnPC has different glycosylated
forms of the same peptide. Light chain also had decreased MW after
deglycosylation (LCd). Lane 4: The enzyme mixture used in lane 3.using a monoclonal antibody directed against human pro-
tein C zymogen (clone HPC4) was useful for purifying
protein C zymogen from canine fresh frozen plasma. This
method is straightforward and does not require expensive
equipment. The matrix and antibody are coupled as a
commercially available product, which can be used up to 7
to 10 times, according to the manufacturer’s instructions,
without the need for regeneration. The proteins purified
from fresh frozen plasma using this method were identi-
fied to be CnPC based on tandem mass spectrometry and
western immunoblotting. Using a method that quantified
the amidolytic activity of the activated form of the protein,
we showed that such activity was enriched 8.19-fold by
salt precipitation and a further 37.59-fold by immunoaffin-
ity chromatography. A specific antigenic assay for CnPC
was not available at the time of this study, rendering abso-
lute quantification of the yield and purification level of the
final protein preparation impossible.
Clone HPC4 targets the peptide sequence EDQVDPR-
LIDGK in human protein C zymogen [26], and the corre-
sponding sequence in CnPC, TDQIDPRLVNGK, differs at
four of twelve amino acid residues. Despite these differ-
ences, HPC4 showed sufficient cross-reactivity with CnPC
for protein purification and western immunoblotting pur-
poses. It has been suggested that calcium ions expose the
HPC4-binding site by inducing a conformational change
in the protein [26]. Calcium ions may induce a conform-
ational change in CnPC such that differences in primary
amino acid sequence do not affect antibody binding.
In humans, protein C is produced by hepatocytes as a
single-chain protein [27]. During post-translational modi-
fication (PTM), the pre-pro-peptide at the N-terminus is
removed [28]. Additionally, an internal arginine-lysine di-
peptide is removed, resulting in a heavy chain and light
chain linked by a disulphide bond [29]. By performing
densitometry on Western blots, Greffe et al. showed
Figure 4 Canine protein C was not a single-chain polypeptide.
Western blot of 12% SDS-PAGE using GMA-093 (which targets the
heavy chain of human protein C) depicting CnPC purified from
canine plasma by salt precipitation and immunoaffinity chromatography.
Lane 1: Unbound protein fraction from immunoaffinity chromatography
did not contain protein C. Lane 2: Five μg of non-reduced CnPC purified
from canine plasma. Immunoreactivity was detected at ~75 kDa. Lane 3:
Five μg of reduced CnPC purified from canine plasma. Immunoreactivity
was detected at ~49 kDa due to dissociation from the light chain.
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double-chained, while 10% was single-chained [30]. They
also showed that single-chain human protein C had three
isoforms: alpha (MW 62 kDa), beta (MW 58 kDa), and
gamma (MW 55 kDa); that the heavy chain had three
isoforms alpha (MW 41 kDa), beta (MW 37 kDa), and
gamma (MW 34 kDa); and that the light chain had two
isoforms (MW 21 kDa and MW 18 kDa).
Our findings show that, similar to human protein C,
CnPC exists in different glycoforms as well. On reducing
SDS-PAGE, CnPC showed three distinct bands of MW
49 kDa, 44 kDa, and 40 kDa. These bands likely represent
three different glycosylated forms of the heavy chain in
CnPC, as treatment with a mixture of deglycosylation
enzymes reduced these three bands into one single band
and resulted in a decreased in MW. A faint band was
visible at ~75-kDa; this may represent the single-chain
CnPC. Results from LC-MS/MS analysis did confirm the
presence of protein C in this band, and no immunoreac-
tivity with HPC4 was detected in this region on western
immnoblotting of the reduced form of the protein. Weconcluded that further studies were necessary to confirm
the presence of single-chain CnPC in plasma.
We further determined three N-linked glycosylation sites
on the CnPC. However, no further studies were performed
to determine the biological significance of the glycans
present at these sites. In humans, glycans on protein C
appear to affect the functional properties of activated
protein C, and the effect of glycosylation at Asn329 is best
described among all the N-linked glycosylated sites. This
site is conserved across many mammalian species [10].
Compared to wild-type APC, a recombinant APC variant
with the glycan eliminated at Asn329 (ACP-N329Q)
showed enhanced endothelial barrier protective function by
6-fold and improved anti-apoptotic function by 30-fold in
endothelial cells treated with staurosporine. The effects of
Asn329 on anticoagulation are not as well defined. APC-
N239Q increased the anticoagulant effects [10,31], but
naturally occurring protein C with a mutation at this site
(N329T) showed decreased rate in deactivation of FVa
following purification from plasma [32].
Canine protein C isolated by the method described here
not only preserved the immunogenic properties of the
protein, as demonstrated by Western immunoblotting, but
also the amidolytic and anticoagulant properties. A com-
mercially available protein C assay has been validated for
measuring protein C activity in canine plasma [24]. This
assay is based on the amidolytic activity of activated protein
C on a chromogenic substrate, which yields a quantifiable
change in absorbance upon cleavage by activated protein C.
In this study, we showed that CnPC purified by the
described method was activatable by Protac and retained its
amidolytic properties. Similarly, following ex vivo activation
with Protac, CnPC inhibited FV and FVIII activities in a
dose-dependent manner, as expected. It is known that
human APC inhibits FV and FVIII activities by proteolysis
of these factors [1,2]. The same mechanisms are presum-
ably present in dogs. Compared to human protein C,
relatively little is known about CnPC.
Currently, the main clinical application of protein C in
veterinary medicine is the differentiation of microvascular
dysplasia and portosystemic vascular anomaly in dogs [33].
Combined with other clinical and laboratory data, plasma
protein C activity could be used to distinguish portosyste-
mic vascular anomaly from microvascular dysplasia [33].
Although not routinely performed, plasma protein C levels
were found to have prognostic value in canine sepsis [13].
Clinical application of purified CnPC is not shown in this
manuscript or described elsewhere and warrants further
investigation.
Conclusions
We showed that a functional protein C zymogen could be
purified by salt precipitation followed by immunoaffinity
chromatography using a commercially available matrix
Figure 5 Peptides derived from purified CnPC deglycosylated with PNGaseF in 18O-labeled water. The complete sequence was predicted
from cDNA amplified by Leebs et al. and confirmed in our lab. Fully identified peptides are indicated in blue; peptides with matching sequences
but incorrect masses are indicated in grey. Three (Asn139, Asn202, and Asn289) of the potential N-linked glycosylated sites showed a 3-dalton
increase in mass, consistent with deamidation of the asparagine residue and incorporation of an 18O atom. The fourth potential N-linked glycosylated
site (Asn350) was not captured on mass spectrometry on multiple attempts. Therefore, the glycosylation status of this site remains unknown. Natural
deamidation (i.e. 1-dalton increase in mass at sites with asparagine that is not part of the N-X-S/T sequon or glutamine) was rare.
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activation with Protac, the purified protein retained its
amidolyic, anti-FV, and anti-FVIII properties. We con-




All procedures were carried out with the approval of the
Animal Care Committee of the University of Guelph and in
compliance with the guidelines provided by the Canadian
Council on Animal Care, and informed client consent was
obtained. Healthy adult dogs were selected for blood
donation based on clinical history, physical examination,
routine blood testing that included complete blood count
and biochemistry, urinalysis, and testing for heartworm,
erhrlichiosis, Lyme disease, anaplasmosis, and hemoplasmosis.Approximately 450 mL of whole blood was collected
aseptically by a trained veterinary technician from the jugu-
lar vein into a bag containing citrate-phosphate-dextrose
and Optisol (sodium, dextrose, adenine, and mannitol)
(Teruflex Blood Bag, Terumo, Somerset, NJ) with constant
mixing during collection. The bag was immediately centri-
fuged at 5,000 g at 4°C for 8 min, followed by immediate
separation of the plasma from other blood components
into the attached satellite bag. The plasma was stored at
-20°C for up to one year, after which the fresh frozen
plasma was moved to storage at -70°C for up to two years.
Salt precipitation
Unless specified, all procedures described below, including
centrifugation, were performed at 4°C. All reagents and
containers were pre-chilled. Where protease inhibitors were
used, they were prepared by dissolving tablets containing a
Figure 6 N-linked glycosylation mapping by IGOT showing three N-linked glycosylated sites. Tandem mass spectra of peptides showing a
3-dalton increase in mass at Asn139 (A), Asn202 (B), and Asn289 (C) after digestion with PNGase F in 18O-labeled water, suggesting that this site
was previously glycosylated.
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Figure 7 Activation of CnPC by Protac, followed by detection of amidolytic activities with Spectrozyme. All measurements were
performed in duplicate, and the average of the two measurements was used as one true experimental replicate. Activity levels were expressed in
optical density units measured at wavelength =405 nm. Each data point shown is the mean (±SEM) of three experiments using plasma from
three different dogs. (A) Amidolytic activities detected at ten time points following addition of Spectrozyme. These results show that purified
CnPC was activatable and retained its amidolytic activities. (B) Linear regression analysis depicting the relationship between the amount of
amidolytic activities detected (expressed by optical density measured at wavelenghth =405 nm) and concentration of CnPC present at various
time points. These results show that the linear range of 0–10 μg/mL in this assay was valid if the samples were analyzed within 5 minutes
following addition of Spectrozyme. Each point is the mean (±SEM) of three experiments using plasma from three different dogs. The dotted lines
delineate the 95% confidence intervals for the curves. (C) Activation of protein C in canine plasma and a plasma fraction obtained following
barium chloride and ammonium sulphate precipitation. Final total protein concentration was adjusted to 100 ng/mL. Protein C was activated by
Protac, a specific activator of protein C, followed by detection with the chromogenic substrate Spectrozyme. Measurements were taken at ten
time points following addition of Spectrozyme in the system.
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Protease Inhibitor Cocktail Tablets, Roche, Laval, QC) in
the solution specified in each of the following steps
described below so that the final concentration duringincubation, centrifugation, or washing was one tablet per
50 mL of solution, as suggested by the manufacturer.
A bag of fresh frozen plasma was thawed in a cool water
bath and divided into 40-mL aliquots in 50-mL BD Falcon
Figure 8 The effects of purified CnPC on the activities of FV and FVIII in canine plasma. Canine plasma pooled from ten dogs and used as
a calibrator. For calibration (A and B), the activity level of each coagulation factor in undiluted plasma pool was designated to be 100%; and five
2-fold dilutions yielded activity levels of 50%, 25%, 12.5%, 6.25%, and 3.125%. The activity level of each factor was expressed as a modified APTT,
which reflected the abilities of the calibrators to correct the APTT in plasma deficient of a specific coagulation factor. All samples were analyzed
in duplicate and the average of the two measurements was used as one true replicate for statistical analysis. Each data point represents the mean
(±SEM) of five replicates. The modified APTTs generated in the presence of activated CnPC were compared against a calibration curve generated
within the same assay. Percent activity of FV or FVIII was plotted against concentration of the purified canine protein (C and D). Each data point
depicted represents the mean (±SEM) of five replicates. The dotted lines delinate the 95% confidence intervals for the curves generated by
linear regression.
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ON). 3.2 mL of 1 M barium chloride (Fisher Scientific,
Ottawa, ON) containing protease inhibitors was added
one drop at a time to each aliquot with periodic mixing.
The plasma mixture was allowed to equilibrate for an
additional one hour with constant mixing, followed by
centrifugation at 1,500 g for 15 min. The supernatant
was discarded, and the precipitate was resuspended in
10 mL of 0.9% NaCl containing protease inhibitors.
This plasma protein fraction was centrifuged at 1,500 g
for 15 min. After two such washes, the precipitate from
two of the original 40-mL plasma aliquots was resus-
pended in 10 mL of 0.2% EDTA containing protease in-
hibitors. This suspension was allowed to equilibrate for
30 min with constant mixing. Ammonium sulphate
pellets (Fisher Scientific, Ottawa, ON) were added to the
suspension in small quantities with periodic mixing to
achieve a final saturation level of 40% (243 mg per mL so-
lution). This was followed by 10 min of constant mixing
to ensure complete solubilization of the ammonium
sulphate pellets and equilibration. The suspension wascentrifuged at 1,500 g for 30 min. The supernatant was
separated. Ammonium sulphate pellets were added in the
same manner described above to achieve a final saturation
level of 65% (168 mg per mL solution). This was followed
by 10 min of constant mixing and then centrifugation at
1,500 g for 30 min. The supernatant was removed. The
precipitate was dissolved in 2 mL of water. A buffer
exchange into 20 mM Tris, pH 7.5, containing 0.1 M
sodium chloride, 1 mM calcium chloride, and protease
inhibitors was performed immediately using 15-mL
Amicon Ultra filter units with molecular weight cut-off
of 30 kDa (Millipore, Billerica, MA). After the final spin,
the retentate was resuspended in the same buffer contain-
ing protease inhibitors so that proteins isolated from two
of the original 40-mL plasma aliquots was resuspended in
1 mL of solution.
Immunoaffinity chromatography
The following procedure was carried out at 4°C with
chilled reagents and containers. The same protease inhibi-
tor tablets were used in the same manner as described
Figure 9 Digestion of CnPC with Protac. (A) Silver stained non-reduced 12% SDS-PAGE depicting the plasma protein fractions obtained over
the course of purification of protein C from canine plasma. Five μg of protein C sample (zymogen or activated) was loaded into each lane. Lane
1: Molecular weight markers (3 μL). Lane 2: CnPC purified from canine plasma. Lane 3: CnPC following incubation with Protac, a specific activator
of protein C; note the decrease in MW of activated CnPC (Ac) and small amount of undigested zymogen form (Zm). Lane 4: Protac purchased
commercially. (B) Western blot of the adjacent SDS-PAGE (A) with a polyclonal antibody against the peptide EDQVDPRLIDGK found in human
protein C zymogen, but not in the activated form of protein C. Lane loads were the same as (A). An immunoreactive protein fraction was
detected in the undigested sample. Following incubation with Protac, the amount of immunoreactive protein (Zm) was significantly decreased.
The activated form of the protein (Ac) was, as predicted, not immunoreactive to the primary antibody.
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refers to a commercially available product (Anti-Protein C
Affinity Matrix; Roche, Laval, QC), which consists of
agarose beads coupled to a monoclonal antibody (clone
HPC4; mouse IgG1κ) against a 12-amino acid sequence
(EDQVDPRLIDGK) of human protein C.
One mL of matrix was packed in the column by gravi-
tation. The matrix was equilibrated with 10 bed-volumes
of equilibration buffer (20 mM Tris, pH 7.5, containing
0.1 M sodium chloride, 1 mM calcium chloride). The
buffer was drained. The bottom end of the column was
capped and 1 mL of equilibration buffer containing pro-
tease inhibitors was applied to the matrix. One mL of
the plasma protein suspension obtained after barium
chloride and ammonium sulphate precipitation was ap-
plied to the matrix. The final concentration of calcium
chloride was adjusted to 1 mM. The top of the column
was capped. The column, now containing the proteins
and the matrix, was inverted a few times to loosen the
matrix, followed by gentle constant mixing on an end-
to-end rocker for two hours. The matrix was then
allowed to settle for 10 min. The bottom was uncapped
and the unbound protein fraction was allowed to drain.
A 23-g needle was applied to the bottom of the column.
This set-up resulted in a flow rate of approximately
0.5 mL per minute. The matrix was washed with 30 bed-
volumes of wash buffer (20 mM Tris, pH 7.5, containing
1.0 M sodium chloride, 1 mM calcium chloride) contain-
ing protease inhibitors. A clean cap was applied to the bot-
tom of the column. Five mLs of elution buffer (20 mM
Tris, pH 7.5, containing 0.1 M sodium chloride and 5 mMEDTA) was applied to the matrix, followed by 30 minutes
of incubation without mixing. The bottom of the column
was uncapped and the 5 mL of elution buffer, now con-
taining the eluted proteins, was collected through a fresh
23-g needle. A buffer exchange into the equilibrium buffer
was performed using 4-mL Amicon Ultra filter units with
molecular weight cut-off of 30 kDa (Millipore, Billerica,
MA). The retentate was concentrated to 250–500 μL in
the last spin.
SDS-PAGE
The eluted proteins were subjected to one-dimensional
SDS-PAGE under both denaturing and non-denaturing
conditions. Buffers were reconstituted from stock solu-
tions (Bio-Rad, Mississauga, ON) for a modular Mini-
Protean II system (Bio-Rad, Mississauga, ON). Laemmli
sample buffer (Bio-Rad, Mississauga, ON) and β-
mercaptoehthanol (Sigma-Aldrich, Oakville, ON) were
purchased and used according to the manufacturer’s in-
structions. Briefly, 1 part β-mercaptoethanol was added
to 9 parts of Laemmli sample buffer. For denaturing
SDS-PAGE, 5 μg of proteins was combined with this
sample buffer at a 1:1 (v:v) ratio, followed by incubation
at 65°C for 10 minutes. For non-denaturing SDS-PAGE,
5 μg of eluted proteins was directly combined with the
Laemmli sample buffer at a 1:1 (v:v) ratio and kept at
room temperature prior to electrophoresis without
addition of β-mercaptoethanol. The protein samples
were loaded into sample wells of a 1.0-mm thick, 15%
Tris-HCl polyacrylamide gel and then subjected to
SDS-PAGE at 220 V on ice for 75 min. The gels were
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bands. Briefly, the gels were fixed in a solution of 40%
ethanol and 10% glacial acetic acid, followed by rinsing
with 20% ethanol and then water. The gels were then in-
cubated with 0.2 g/L of sodium thiosulfate for one min,
followed by rinsing with water, and then incubation
with 2 g/L of silver nitrate for 30 minutes. Following a
brief rinse with water, the gels were developed in a solu-
tion containing 30 g/L of sodium carbonate, 1.4 mL/L
of 37% formaldehyde, and 10 mg/L of sodium thiosul-
fate for up to 15 min until the desired intensity of the
protein bands was achieved. Molecular weights of the
visible bands were compared against markers of known
molecular weight (Precision Plus Protein WesternC
Standards, Bio-Rad, Mississauga, ON).
Mass spectrometry and protein identification
The silver-stained protein bands visible on SDS-PAGE
were excised, placed in siliconized microcentrifuge tubes
containing 1% v/v acetic acid, and submitted on dry ice for
LC-MS/MS (The Advanced Protein Technology Centre,
Hospital for Sick Children, Toronto, ON). In-gel tryptic di-
gestion was performed as previously described [34]. Briefly,
the silver-stained gel incubated with a solution containing
30 mM of potassium ferricyanide and 100 mM of sodium
thiosulfate at a 1:1 (v/v) ratio for 15 minutes, followed by
rinsing with water and then with 50 mM of ammonium bi-
carbonate. The gel was shrunk with 50% acetonitrile con-
taining 25 mM of ammonium bicarbonate for 10 min. The
proteins were then reduced in 10 mM of dithiothreitol
(DTT) at 56°C for 30 min, followed by alkylation in
100 mM of iodoacetamide for 15 min. The gel was shrunk
for the second time for 15 minutes. The gel was incu-
bated overnight with 50 mM ammonium bicarbonate
containing 13 ng/μL of porcine trypsin (Sequencing
Grade Modified Trypsin, Promega, Madison, WI) at 37°C.
The digested peptides were loaded onto a 150 μm ID pre-
column (Magic C18, Michrom Biosciences, Auburn, CA)
at 4 μL per min and separated over a 75 μm ID analytical
column packed into an emitter tip containing the same
packing material. The peptides were eluted over 60 mi-
nutes at 400 nL per minute using a 0–40% acetonitrile
gradient in 0.1% formic acid into a linear ion trap mass
spectrometer (LTQ-Orbitrap) (Thermo-Fisher, San Jose,
CA) operated in a data-dependent mode. One MS
followed by 6 MS/MS scans were obtained per cycle. Tan-
dem mass spectra were extracted by Extract_msn.exe 4.0
and Bioworks 3.3 (Thermo-Fisher, San Jose, CA). Charge
state deconvolution and deisotoping were performed. The
generated data files were analyzed using Mascot 2.3
(Matrix Science, London, UK; version Mascot). Mascot
was set up to search the NCBInr_20090719 database (se-
lected for Canis lupus familiaris, 34574 entries) assuming
that digestion enzyme was non-specific. Mascot wassearched with a fragment ion mass tolerance of 0.50 Da
and a parent ion tolerance of 20 ppm. Iodoacetamide de-
rivative of cysteine was specified in Mascot as a fixed
modification. Deamidation of asparagine and glutamine
and oxidation of methionine were specified in Mascot as
variable modifications. Scaffold (version Scaffold_3_00_08,
Proteome Software Inc., Portland, OR) was used to validate
MS/MS based peptide and protein identifications. Peptide
identifications were accepted if they could be established at
greater than 95.0% probability as specified by the Peptide
Prophet algorithm [35]. Protein identifications were
accepted if they could be established at greater than
99.9% probability and contained at least 5 identified
peptides. Protein probabilities were assigned by the
Protein Prophet algorithm [36]. Proteins that contained
similar peptides and could not be differentiated based
on MS/MS analysis alone were grouped to satisfy the
principles of parsimony.
Western immunoblotting
Following SDS-PAGE, the separated proteins were elec-
trotransfered at 100 V for 1 h onto Immobilon-P polyviny-
lidene fluoride (PVDF) membrane (Millipore, Billerica,
MA). The membrane was blocked for 2 h with phosphate-
buffered saline, pH7.4 containing 0.1% Tween-20 (PBS-T)
and 5% non-fat skim milk. The membrane was then incu-
bated with polyclonal rabbit anti-protein C (HPC4) tag
antibody (GenScript, Piscataway, NJ) at 1:1,000 dilution
(5 × 10-4 μg/μL) in PBS-T containing 5% non-fat skim milk
for 60 min, followed by three 10-min washes in 20 mL of
PBS-T. The membrane was then incubated with horserad-
ish peroxidase (HRP)-conjugated polyclonal goat anti-
rabbit IgG antibody (Dako, Denmark) at 1:2,000 dilution
(1.25 × 10-4 μg/μL) in PBS-T containing 5% non-fat skim
milk for 2 h and washed three times as described above.
The membrane was then incubated with HRP conjugate for
the MW standards (Precision Plus Protein StrepTactin-
HRP Conjugate, Bio-Rad, Mississauga, ON) at 1:5,000 dilu-
tion (2 × 10-4 μg/μL) in PBS-T containing 5% non-fat
skim milk for 20 min, followed by three washes as de-
scribed above. The membrane was then incubated with
the Amersham ECL Western Blotting Detection Reagents
(GE Healthcare, Buckinghamshire, UK) according to the
manufacturer’s instructions. Chemiluminesence was de-
tected using the ChemiDoc XRS + System with Image Lab
Software (BioRad, Mississauga, ON). Relative intensity of
detected bands was determined by densitometry using
Image Lab Software.
Additionally, the purified proteins were subjected to
Western immunoblotting using a mouse monoclonal anti-
human protein C heavy chain antibody, clone GMA-093
(Upstate, Lake Placid, NY), as primary antibody at 1:1,000
dilution (1 × 10-3 μg/μL) and a polyclonal rabbit anti-mouse
IgG antibody coupled to horseradish peroxidase (Abcam,
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(5 × 10-4 μg/μL). Procedures for Western immunoblotting
and detection of immunoreactive proteins were carried out
in the same way as described above.
N-linked glycosylation mapping
For visualization of deglycosylated proteins on SDS-
PAGE, the isolated proteins were incubated with a Protein
Deglycosylation Mix (New England Biolabs, Mississauga,
ON) according to the manufacturer’s instructions. Briefly,
9 μg of purified proteins were incubated with 40 mM
DTT and 0.5% SDS at 100°C for 10 min and cooled on
ice for 10 s. The denatured proteins were then incu-
bated with 50 mM sodium phosphate, pH7.5, containing
1% NP-40, O-glycosidase (4 × 103 units/μL), beta-N-
acetylglucosaminidase (4 × 10-1 units/μL), neuraminidase
(5 units/μL), beta-1-4-galactosidase (8 × 10-1 units/μL),
and PNGase F (5 × 10 units/μL) for 4 h at 37°C in a 50-μL
reaction. Purified proteins subjected to the same pro-
cedures in the absence of the deglycosylation enzymes
served as a negative control. Bovine fetuin (a glycosylated
protein) was used as a positive control. SDS-PAGE
and silver-staining were performed as described above.
Proteins isolated from three different dogs were studied.
To identify potential N-linked glycosylated sites, the pre-
dicted amino acid sequence of CnPC was searched for the
consensus sequences N-X-T and N-X-S [19]. For IGOT
[21], 10 μg of purified protein was first concentrated and
diafiltered into 10 μL of 18O-labelled water (97% atom la-
belled) (Sigma-Aldrich, Oakville, ON) using a Microcon
Centrifugal Filter Device with molecular weight cut-off at
10 kDa (Millipore, Billerica, MA). Following addition of
2 μL of 400 mM DTT and 5% SDS, the proteins were de-
natured (total volume: 12 μL) at 100°C for 10 min and
cooled on ice for 10 s. The following were then added to
the mixture: 20 μL of 18O-labelled water, 4 μL of 500 mM
sodium phosphate, pH7.5, 2 μL of 10% NP-40, and 2 μL of
PNGase F (5 × 102 units/μL). This mixture was incubated
for 4 h at 37°C with periodic mixing. At the end of
the reaction period, the mixture was diafiltered into
TBS constituted with Milli-Q (mostly H2
16O) water
using a Microcon Centrifugal Filter Device with
molecular weight cut-off at 10 kDa (Millipore, Billerica,
MA). The proteins were subjected to trypsin digestion
and LC-MS as described above. The software PEAKS
(Bioinformatics Solutions, Waterloo, ON) was used to
search for +3 mass unit shifts at the predicted N-linked
glycosylated sites.
Digestion of CnPC with Protac
Five μg of purified proteins in TBS were incubated with
0.1 unit of Protac (Sekisui Diagnostics, Stamford, CT),
an activator of human [22] and canine [24] protein C
and a substance derived from the venom of Agkistrodonc. contortrix, or same volume of TBS at 37°C for 15 min.
All samples were then subjected to non-reducing 12%
SDS-PAGE, followed by silver-staining or Western im-
munoblotting using a polyclonal rabbit anti-protein C
(HPC4) tag antibody as described above.
N-terminal sequence determination
The N-termini of the heavy chain, light chain, and
Protac-digested heavy chain were analyzed by Edman
degradation [37]. Purified proteins were subjected to redu-
cing 12% SDS-PAGE and electrotransfered overnight at
30 V in CAPS buffer (Sigma-Aldrich, Oakville, ON) onto
Immobilon-PSQ PVDF membrane (Millipore, Billerica,
MA). The membrane was incubated for 10 mins in 0.2%
(w/v) Ponceau S (Sigma-Aldrich, Oakville, ON) in 1% (v/v)
acetic acid and washed three times in Milli-Q water. It was
then stored in a moist chamber and submitted for sequen-
cing (The Advanced Protein Technology Centre, Hospital
for Sick Children, Toronto, ON). Stained protein bands
were excised and analyzed by the Procise Protein Sequen-
cing System (Applied Biosystems, Foster City, CA) as previ-
ously described [38].
Detection of amidolytic activity
The amidolytic activity of the purified protein was mea-
sured by a method modified from previously described
studies [22-24,39] using Protac and Spectrozyme [H-D-(γ-
carbobenzoxyl)-lysyl-prolyl-arginine-paranitroanilide diace-
tate salt], a chromogenic substrate for activated protein C.
Protac (Sekisui Diagnostics, Stamford, CT) and Sepctro-
zyme (Sekisui Diagnostics, Stamford, CT) were reconsti-
tuted with sterile water to 0.5 unit/mL and 10 mM,
respectively. Spectrozyme was further diluted by combining
7 parts of 50 mM Tri-HCl, pH 8.4 and 1 part Spectrozyme.
The purified protein was adjusted to 0, 20, 40, 60, 80, and
100 μg/mL by dilution with TBS. Fifty μL of purified pro-
tein was incubated with 50 μL of Protac (0.5 unit/mL) for
5 min at 37°C. Forty μL of this mixture was placed in each
well in a 96-well plate. One hundred and eighty μL of Spec-
trozyme was added to each of all samples simultaneously
using a multi-channel pipette. Final protein concentrations
in the samples were 0, 2, 4, 6, 8, and 10 μg/mL. Absorbance
at λ = 405 nm was measured at 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and
10 min following addition of Spectrozyme using a BioTek
Synergy HT plate reader (BioTek, Winooski, VT) and
Gen5 version 1.11 (BioTek, Winooski, VT). All samples
were analyzed in duplicate and the average of the two mea-
surements was used as one true replicate for statistical ana-
lysis using GraphPad Prism (GraphPad Software, La Jolla,
CA). For each concentration of protein (final concentra-
tions: 0, 2, 4, 6, 8, 10 μg/mL), three replicates were obtained
using proteins isolated from three different dogs. The mean
absorbance ± standard error of mean (SEM) for each time
point was plotted against time. For each time point, the
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of purified protein. Additionally, amidolytic activities in ca-
nine plasma and the salt precipitate obtained following bar-
ium chloride and ammonium sulphate precipitation were
determined in a similar manner using final protein concen-
tration of 100 μg/mL.
Canine factor V & VIII assays
Canine coagulation factor assays were performed based on
published methods [40,41] using the KC 4 Delta coagula-
tion analyzer (Stago, Parsipanny, NJ). Canine plasma pool
was generated by pooling 0.5–2 mL of citrated plasma from
each of ten clinically healthy adult dogs. The plasma pool
was stored in aliquots at -70°C. For calibration, the activity
level of each coagulation factor present in the undiluted
plasma pool was designated to be 100% in the calibration
process; and the plasma pool was serially diluted five times
by a factor of two to obtain samples with activity levels of
50%, 25%, 12.5%, 6.25%, and 3.125%. The isolated canine
protein was activated with Protac as described above and
prepared by dilution with TriniCLOT imidazole buffer
(Diagnostica Stago, Toronto, ON) to obtain these concen-
trations of 1, 0.8, 0.6, 0.4, 0.2 and 0 μg/μL. Fifty μL of factor
V-deficient plasma (Trinity Biotech, Jamestown, NY) or
factor VIII-deficient plasma (Trinity Biotech, Jamestown,
NY) was incubated with 50 μL of pooled canine plasma
and 3 μL of purified protein for 60 s at 37°C with constant
mixing, followed by incubation with 10 μL of TriniCLOT
aPTT reagent S (Diagnostica Stago, Toronto, ON) at 37°C
for 300 sec. One hundred μL of 0.025 M CaCl2 (Diagnos-
tica Stago, Toronto, ON) was added to the mixture and the
time from then to clot formation was recorded [referred to
as modified activated partial thromboplastin time (APTT)].
All samples were analyzed in duplicate and the average of
the two measurements was used as one true replicate for
statistical analysis using GraphPad Prism (GraphPad Soft-
ware, La Jolla, CA). The clotting times were compared
against a standard curve generated within the same assay
using canine pooled plasma diluted with TriniCLOT imid-
azole buffer. Percent activity of FV or FVIII was plotted
against concentration of the purified canine protein.Abbreviations
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